Background: The role of the adenosine (ADO) suppression pathway, specifically CD39-expressing and CD73-expressing CD4 þ T cells in HIV-1 infection is unclear.
Introduction
Effective antiretroviral therapy (ART) has led to a significant increase in the life expectancy of individuals with HIV-1 infection [1] . Despite this improvement, mortality rates in HIV-1-infected individuals on ART are still higher than those in the general population [2, 3] . In HIV-1-infected individuals, persistent immune activation has been associated with disease progression [4, 5] . It is hypothesized that the increased risk for end-organ diseases [6] [7] [8] and death is also due to persistent immune activation [9] . Moreover, increased frequency of activated immune cells has been linked to early senescence and increased morbidity in HIV-1 infection [10] [11] [12] .
Excessive immune activation in HIV-1 infection has been attributed to persistence of the virus in the circulation [13] . However, chronic immune activation is also seen in individuals with undetectable plasma viremia. Thus, immune activation could alternatively be due to the preferential depletion of CD4 þ T cells in the gut mucosa by HIV-1 infection, leading to enhanced translocation of microbial products to the circulation [14] [15] [16] ; reactivation of other viruses such as cytomegalovirus [17] ; and dysregulation of the T-cell homeostasis [18] .
The role of regulatory T cells (Treg) in HIV-1-associated immune activation and disease progression remains unclear. It has been shown that Treg can control HIV-1 virus replication in conventional T cells (T conv ) but also suppress functions of activated T conv [19, 20] . Moreover, HIV-1-infected individuals have an increased frequency of Treg, which correlates with progressive disease [19, 21] . The Treg subset responsible for these effects consists of CD4 þ CD39 þ CD25 þ FOXP3 þ T cells. CD39 is an ectoenzyme, which, in concert with CD73, hydrolyzes ATP to adenosine (ADO), an important regulatory factor in inflammation [22] . Although murine Treg express CD39 and CD73 [23, 24] , few human CD4 þ T cells (<0.1%) coexpress both enzymes on the cell surface [25] . Recently, the CD39/ADO axis has been linked to Tregmediated suppression in cancer as well as inhibition of HIV-1 replication [20, 26] . However, little is known about CD4 þ T-cell expression of CD73 in HIV-1 infection.
We hypothesized that extracellular ADO-mediated suppression plays a role in HIV-1-associated immune activation and that CD4 þ CD73 þ T cells are essential in this immunoregulatory mechanism. We, therefore, conducted a cross-sectional study within the Multicenter AIDS Cohort Study (MACS) to seek evidence that CD4 þ CD73 þ T cells regulate activation of T cells in the blood of HIV-1-positive individuals. We show that CD4 þ CD73 þ T-cell numbers were decreased in HIV-1positive individuals regardless of viral suppression. Depletion of CD4 þ CD73 þ T cells correlated with increased numbers of activated CD4 þ and CD8 þ T conv , suggesting that CD4 þ CD73 þ T cells play a previously unrecognized role in regulating HIV-1-associated immune activation.
Materials and methods

Study population and collection of peripheral blood mononuclear cells
This study was part of the MACS, an investigation of the natural history of HIV-1 infection in MSM, and was approved by the University of Pittsburgh Institutional Review board (IRB#9505118). Blood was obtained from HIV-1-positive individuals (n ¼ 36) and agematched HIV-1-seronegative controls (NC; n ¼ 10). HIV-1-positive individuals included ART-naive individuals (noART; n ¼ 9) and ART-treated, virally suppressed individuals with CD4 þ T-cell counts more than 500 cells/ ml (ART500; n ¼ 15) and those with CD4 þ T-cell counts 350 cells/ml or less (ART350; n ¼ 12). For additional functional studies, blood was obtained from ART-treated, virally suppressed MSM (CD4 þ T-cell counts >500) in the Pitt Treatment and Evaluation Unit (PTEU, n ¼ 6) and buffy coats from healthy anonymous donors (Central Blood Bank, Pittsburgh, USA). All participants gave written informed consent. Heparinized blood (20 ml) was used for recovery of plasma and peripheral blood mononuclear cells (PBMCs) by Ficoll-Hypaque gradient separation (GE Healthcare Bioscience, Piscataway, New Jersey, USA). EDTA-anticoagulated blood was used for single copy assays (SCAs) and for determining the frequency and absolute numbers of CD3 þ CD4 þ T cells and CD3 þ CD8 þ T cells per ml by flow cytometry and the TetraONE system, respectively (Beckman-Coulter, Brea, California, USA).
Flow cytometry reagents
The following antihuman monoclonal antibodies (mAbs) were used for staining: CD4-PC5 (13B8.2), CD8-PE/ PC5 (SFCI21Thy2D3), CD26-PE (4EL-1C7), HLA-DR-ECD (Immu357), CD45RO-ECD (UCHL1) (Beckman Coulter); CD39-FITC/PE-Cy7 (A1), CD38-FITC (HIT2), tumor necrosis alpha (TNF-a)-eFluor450 (MAb11), FOXP3-FITC (PCH101) (eBioscience, San Diego, California, USA), CD4-AF700 (RPA-T4), interleukin 2 (IL-2)-APC (5344.111), (Biolegend, San Diego, California, USA), CD73-PE (AD2) (BD Pharmingen, San Diego, California, USA); CD25-PE (4E3) (Miltenyi, Auburn, California, USA), including their respective isotypes as negative controls. All mAbs were pretitrated to determine the optimal staining dilution.
Surface and intracellular staining for flow cytometry
PBMCs from NC and HIV-1-positive individuals (MACS) were incubated with mAbs in 50 ml phosphate-buffered saline for 30 min at room temperature. For intracellular staining of FOXP3 and cytokines, cells were fixed and permeabilized using a commercial staining kit (eBioscience) [27] . Flow cytometry was performed using an EPICS XL-MCL and Galliosflow cytometer equipped with Expo32 and Kaluza software (Beckman Coulter). The acquisition and analysis gates were restricted to the lymphocyte gate based on forward and side scatter. At least 5 Â 10 5 events were acquired for analysis.
Measurement of residual plasma viremia by single copy assay
Low-level residual viremia of less than 50 copies/ml of plasma was quantified by SCA as previously described [28] . Briefly, HIV-1 virions were pelleted from plasma by ultracentrifugation and digested with proteinase K. Guanidinium isothiocyanate supplemented with glycogen was added, and RNA was pelleted with isopropanol, washed with ethanol, and resuspended in Tris-HCl. The RNA was reverse transcribed to cDNA, which was then quantified by real-time PCR using primers specific for a conserved region of Gag.
Measurement of plasma C reactive protein
Plasma of NC and HIV-1-positive individuals was assayed for C reactive protein (CRP; Human Singleplex Bead Kit and Human Extracellular Protein Buffer Reagent Kit; Invitrogen, Grand Island, New York, USA) using the Luminex (Austin, Texas, USA) fluorescent microbead platform and the manufacturer's protocol.
Mass spectrometric analysis CD39 þ and CD73 þ T-cell subsets were separated by the ectonucleotidase-specific biotinylated mAbs and antibiotin magnetic beads using AutoMACS (Miltenyi). For determination of ATP and 5 0 -AMP hydrolysis, CD4 þ T cells (either CD39 þ or CD73 þ ) were incubated with 20 mmol/l ATP for various time periods. Controls included cells alone or ATP alone. Supernatants were collected, centrifuged, boiled to inactive ADO-degrading enzymes, and purines were measured using liquid chromatography-tandem mass spectrometer as previously described [29] .
Evaluation of intracellular cyclic adenosine monophosphate levels CD4 þ T cells were separated from PBMCs of NC and HIV-1-positive individuals using CD4 þ T-cell separation kit (Miltenyi). Frequency of CD4 þ CD39 þ and CD4 þ CD73 þ T cells were determined. Cells were cultured in complete Roswell Park Memorial Institute (RPMI) medium for 48 h with anti-CD3/CD28 microbeads in the presence of IL-2 (150 IU/ml), washed, placed in a 96-well plate at 10 6 cells/well, and incubated with or without ATP (50 mmol/l). Concentration of intracellular cyclic adenosine monophosphate (cAMP) was measured using Amersham cAMP Enzyme Immunoassay Biotrak System (GE Healthcare).
In-vitro suppression of T cells by adenosine
PBMCs (10 6 ) from NC or HIV-1-positive individuals in the ART500 group were activated with Staphylococcal enterotoxin B (SEB, 1 mg/ml; Sigma-Aldrich, St Louis, Missouri, USA) in the presence of ADO (0.1-1 mmol/l) in RPMI medium for 6-12 h at 378C. T-cell immune activation and expression of TNF-a and IL-2 were measured using flow cytometry. Cells were stained as described above. Brefeldin A (10 mg/ml, Sigma-Aldrich) was added for cytokine measurements. The ADOreceptor antagonist DPSPX (100 mmol/l, Sigma-Aldrich) was added for blocking experiments.
CD4 R CD73 R suppression assays For suppression of T-cell immune activation and TNF-a and IL-2 secretion, PBMCs were obtained from PTEU participants. CD4 þ CD73 neg and CD4 þ CD73 þ cells were separated by magnetic beads as described above. CD4 þ CD73 neg cells were stimulated with SEB (1 mg/ml) with or without CD4 þ CD73 þ suppressor cells for 12 h. Levels of T-cell activation and TNF-a and IL-2 expression were measured as described above. For suppression of T-cell proliferation by CD4 þ CD73 þ cells, we obtained PBMCs from NC. CD4 þ CD73 neg and CD4 þ CD73 þ T cells were also separated by magnetic beads as described above. Carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4 þ CD73 neg responder cells (n ¼ 10 5 ) were stimulated with SEB in 96-well plates for 5 days. Proliferation of responder cells was measured by single-color flow cytometry.
Statistics
Data are expressed as medians. For samples with nonparametric distribution of values, Kruskal-Wallis and two-tailed exact Wilcoxon-Mann-Whitney tests were applied using SPSS software (IBM, Version 19). Correlations were calculated by the Spearman test. For the demographic data, groups were compared by Kruskal-Wallis with Dunn's Multiple Comparison Test using GraphPad Prism v5.04. P values of 0.05 or less and R 2 values at least 0.4 were considered to be significant.
Results
Study populations
The majority of MACS participants on ART were infected with HIV-1 more than 10 years (16/29) as compared to the nine untreated participants who were infected less than 10 years (Table 1) . Of the 29 participants on ART, the majority were on a nonnucleoside reverse transcriptase inhibitor or protease inhibitor-based regimen. CD4 þ T-cell counts in the three groups of HIV-1infected individuals were lower than those in the NC. CD4 þ T-cell counts in the noART group were similar to those in the ART500 group.
Ectonucleotidase expression in CD4 R T cells
Whereas the absolute numbers of CD4 þ CD39 þ and CD4 þ CD73 þ T-cell subsets were decreased in HIV-1positive individuals compared to NC, only the frequency of CD4 þ CD73 þ T cells was decreased in HIV-1-positive individuals as compared to NC (8.8 vs. 5.2%; P ¼ 0.005; Fig. 1a ,b). In HIV-1-positive individuals and NC, CD39 and CD73 were expressed in different CD4 þ T-cell subsets (Fig. 1c ). Both subsets belonged to the memory compartment (CD45RO þ ). Commonly used Treg markers CD25 and FOXP3 were not expressed in CD4 þ CD73 þ cells, unlike CD4 þ CD39 þ cells ( Figure  S1 , http://links.lww.com/QAD/A331), as has been previously reported [30] . In contrast to CD4 þ CD39 þ Treg, nearly all CD4 þ CD73 þ T cells were CD26 þ . For all HIV-1-positive individuals, the frequency and absolute numbers of CD4 þ CD73 þ T cells positively correlated with CD4 þ T-cell counts (r ¼ 0.4, P ¼ 0.01 and r ¼ 0.8, P < 0.001, respectively; data not shown), whereas mean percentage of CD4 þ CD39 þ T cells within the shrinking CD4 þ compartment remained comparable to that in NC ( Fig. 1a ). These results suggest that CD4 þ CD73 þ T cells are preferentially depleted in HIV-1-positive individuals.
CD4 R CD73 R T-cell frequency and immune activation Compared to NC, the absolute number and frequency of the CD4 þ CD73 þ T cells were lower in all HIV-1positive groups (Fig. 2a,b) regardless of viral suppression. The lowest absolute numbers of CD4 þ CD73 þ T cells were seen in the ART350 group (15 vs. 89/ml in NC, P < 0.001; Fig. 2a ). In contrast, the frequency of CD4 þ CD39 þ T cells was similar in all four groups, whereas their absolute number was decreased in the noART and ART350 groups (Fig. 2c,d) . As a group, HIV-1-positive individuals had a higher frequency of activated CD4 þ (3.1 vs. 1.8%; P ¼ 0.001) and CD8 þ T cells (6.2 vs. 3.6%; P ¼ 0.01) than NC (data not shown). All four HIV-1-positive groups had a higher frequency of CD4 þ and CD8 þ T cells coexpressing both activation markers than NC ( Fig. 2e,f) . The increased numbers and percentages of activated CD4 þ and CD8 þ T cells of HIV-1-positive individuals corresponded to the decreased numbers and percentages of CD4 þ CD73 þ T cells ( Fig. 2a,b ,e,f).
Negative correlation of CD4 R CD73 R T-cell numbers with activated T cells
In HIV-1-positive individuals, the absolute number of CD4 þ CD73 þ T cells showed an inverse correlation with the frequency of activated CD4 þ (r ¼ À0.5, P < 0.002) and CD8 þ T cells (r ¼ À0.4, P ¼ 0.05) as well as with plasma CRP levels (r ¼ À0.5, P ¼ 0.01; Fig. 3a ). The frequency of CD4 þ CD73 þ T cells was also inversely correlated to that of activated CD4 þ T cells (r ¼ À0.4, P ¼ 0.03; data not shown). In contrast, absolute numbers of circulating CD4 þ CD39 þ T cells in HIV-1-positive individuals did not correlate with the frequency of activated CD4 þ or CD8 þ T cells or with the plasma CRP levels (r ¼ À0.3, P ¼ 0.1; Fig. 3b ). Majority of the individuals in ART350 and ART500 had no detectable viremia by SCA (limit of detection ¼ 0.61 copies/ml). For those with detectable viremia, there was no correlation with T-cell immune activation (Fig. 3c ). These data suggest that the depletion of CD4 þ CD73 þ T cells in HIV-1-positive individuals plays a role in persistent immune activation and inflammation.
Evaluation of adenosine production by CD4 R CD73 R and CD4 R CD39 R T-cell subsets We tested the capability of CD4 þ CD39 þ T cells to hydrolyze exogenous (e) ATP to 5 0 -AMP and of CD4 þ CD73 þ T cells to hydrolyze e5 0 -AMP to ADO using mass spectrometry. The subsets were first separated using magnetic beads (purity >85%; Figure S2 , http:// links.lww.com/QAD/A331). Exogenous ATP was hydrolyzed to 5 0 -AMP only in the presence of CD4 þ CD39 þ T cells (44 AE 5 vs. 8 AE 2 ng/ml, t ¼ 60 min, P ¼ 0.03; Fig. 4a ). 5 0 -AMP produced by CD4 þ CD39 þ T cells was hydrolyzed to ADO only in the presence of CD4 þ CD73 þ T cells (9.1 AE 2.9 vs. 2.7 AE 1.2 ng/ml, t ¼ 60 min, P ¼ 0.03; Fig. 4b ). High levels of ADO were produced only when both T-cell subsets were present. Individually, these cell subsets were inefficient in 1548 AIDS 2013, Vol 27 No 10 converting eATP to ADO. Interestingly, the ability to hydrolyze e5 0 -AMP to ADO was greater in CD4 þ CD73 þ T cells obtained from HIV-1-positive individuals (P ¼ 0.002, Fig. 4c ), despite no difference in expression of CD73 in CD4 þ T cells of HIV-1-positive individuals and NC (data not shown).
Evaluation of cyclic adenosine monophosphate levels in CD4 R T cells
In lymphocytes, ADO mediates suppression by increasing cAMP levels in responder cells. We determined whether eATP-treated CD4 þ T cells of HIV-1-positive individuals (PTEU) had similar cAMP levels as CD4 þ T cells of NC. We found that the addition of eATP to total CD4 þ T cells, which combine the CD4 þ CD39 þ and CD4 þ CD73 þ T-cell subsets, induced a greater increase of cAMP levels in NC than in HIV-1-positive individuals' cells ( Fig. 4d) . These results suggest that in HIV-1 infection, CD4 þ T cells produce less ADO, increase cAMP to a lesser degree and, thus, induce less immunosuppression than CD4 þ T cells of NC. This is likely due to the lower frequency of CD73 þ T cells within the CD4 þ population incubated with eATP in HIV-1positive individuals than in NC (Fig. 4e ). The results are consistent with the decreased numbers of CD4 þ CD73 þ T cells in HIV-1 and with the persistent immune activation seen in HIV-1-positive individuals.
Suppressive activity of exogenous adenosine
We have shown above that low proportions of CD4 þ T cells that express CD73, the rate-limiting enzyme in the ADO pathway, could account for low ADO levels and persistent immune activation in HIV-1-positive individuals. Next, we evaluated a potential role of ADO in suppression of cytokine expression in CD4 þ T cells and CD4 þ and CD8 þ T-cell immune activation following in-vitro stimulation with SEB in NC and HIV-1-positive individuals (PTEU, n ¼ 5, Fig. 5a,b ). In the presence of eADO (250 mmol/l, 6 h), the mean decrease in the percentage of cytokine-expressing CD4 þ T cells was cells. Similar results were obtained with CD8 þ T cells (data not shown). ADO also suppressed T-cell activation.
In the presence of ADO (500 mmol/l, 6 h), the mean decrease in the frequency of activated T cells was 2.7 AE 1.2% for CD4 þ and 2.5 AE 1.6% for CD8 þ T cells (Fig. 5b) . Thus, eADO had considerable inhibitory effects on functions of CD4 þ and CD8 þ T cells of NC and HIV-1-positive individuals.
Suppressive activity of CD4 R CD73 R T cells
In preliminary ex-vivo experiments, we found that CD4 þ CD73 þ T cells did not mediate suppression of TNF-a and IL-2 or CD38/DR expression in activated CD4 þ T cells of HIV-1-positive individuals (PTEU) or NC (data not shown). The ability of CD4 þ CD73 þ T cells to mediate suppression of responder cell proliferation was next evaluated. In CSFE suppression assays, we incubated CD4 þ CD25 neg responder cells alone or in the presence of isolated autologous CD4 þ CD73 þ T cells and observed no suppression of responder cell proliferation by these cells (Fig. 5c ). However, upon addition of e5 0 -AMP to the proliferation assay, increased suppression was observed. These results show that CD4 þ CD73 þ T cells alone cannot mediate suppression. However, when supplemented with eATP in the presence of CD4 þ CD39 þ cells or e5 0 -AMP, they acquire the ability to produce ADO and mediate suppression (Fig. 5a,b ).
Discussion
In chronic HIV-1 infection, it is important to evaluate the integrity of immunoregulatory pathways, as persistent immune activation and increased levels of systemic inflammation go unchecked when immunoregulatory activities are compromised. In this study, we assessed the activity of the ADO suppression pathway, specifically the activity of ectoenzyme-expressing CD4 þ T cells, in HIV-1 infection. Several groups have already reported on CD39 þ Treg during chronic HIV-1. However, data regarding the role of CD4 þ CD73 þ T cells in this disease are not available. As CD73 is a rate-limiting enzyme in the ADO pathway, its presence on a subset of CD4 þ T cells potentially involved in immune regulation implicates ADO in HIV-1 pathogenesis.
We found that CD73 þ CD4 þ T cells represent a functionally and phenotypically distinct subset from CD4 þ CD39 þ FOXP3 þ Treg [20, 31] . Unlike CD4 þ CD39 þ Treg, they do not express FOXP3 and CD25 high . We show that CD4 þ CD73 þ T cells are depleted in HIV-1 infection regardless of virologic suppression and are not completely reconstituted with increasing CD4 þ T-cell counts. Whereas a relative accumulation of Treg has been described during chronic HIV-1 infection [32] , our findings suggest that CD4 þ CD73 þ T cells are preferentially depleted. Possibly, depletion of these ADO-producing cells in HIV-1-positive individuals results in decreased ADO suppression, hence the inability to control persistent T-cell activation. Indeed, we noted inverse correlations between the number of CD4 þ CD73 þ T cells and T-cell activation, as well as plasma CRP levels, which we did not observe with CD4 þ CD39 þ T cells. Furthermore, CD4 þ CD73 þ T cells have increased dipeptidyl peptidase-4 (CD26) expression, which can bind HIV-1 Tat [33, 34] and lead to T-cell suppression. Further investigation should be done to evaluate whether Tatbinding leads to the inhibition of CD73 activity. We also investigated the ability of ectoenzyme-expressing CD4 þ T cells to produce ADO. Our ex-vivo results indicate that CD4 þ CD39 þ T cells require cooperation from CD4 þ CD73 þ T cells for optimal production of ADO, as they are predominantly expressed in different CD4 þ T-cell subsets. Both subsets must work in tandem to convert eATP to ADO, with CD73 serving as a ratelimiting enzyme. ADO, in turn, suppresses functions of activated helper and effector T cells expressing A 2A receptors [35] . Our results suggest that the ability to produce ADO by the two ectoenzyme-expressing CD4 þ T cells is not compromised in HIV-1-positive individuals. In fact, when eATP was added to CD4 þ T cells containing both subsets, cAMP levels increased in CD4 þ T cells obtained from NC and HIV-1-positive individuals. However, this increase in cAMP was greater in cells from NC, suggesting lower ADO engagement in HIV-1positive individuals, which is likely due to lower numbers of CD4 þ CD73 þ T cells. Together, these results suggest that fewer CD4 þ CD73 þ T cells present in HIV-1 infection are responsible for lower ADO production and lesser cAMP upregulation leading to reduced suppression and persistent activation. To confirm that these mechanisms operate in vivo, it would be necessary to measure plasma ADO levels. However, ADO is highly unstable, and direct measurements of plasma levels are unlikely to be reliable and may be too low for measurements by mass spectrometry.
Unlike CD4 þ CD39 þ Treg, which have been shown to mediate suppression by multiple mechanisms [36] in addition to ADO-mediated suppression [26] , the CD4 þ CD73 þ subset does not mediate suppression in CFSE suppression assays. However, by virtue of its ability to produce ADO, this subset can play an important role in immune regulation in HIV-1 infection. Indeed, our results confirm that ADO downregulates T-cell activation as well as TNF-a and IL-2 expression in T cells. Interestingly, Murray et al. [37] reported in 1984 that there was decreased 5 0 nucleotidase (5 0 -NT, CD73) activity in lymphocytes of patients with AIDS and asymptomatic MSM. Thus, early on in the AIDS epidemic, 5 0 -NT activity in T cells had already been considered an important factor in AIDS pathogenesis. CD73 activity can also prevent cardiovascular disease as ADO interferes with cellular adhesive properties in the vascular endothelium, thereby inhibiting atherogenesis [38] . Increased rates of cardiovascular disease and atherosclerosis have been reported in HIV-1-positive individuals despite effective ART [6, 39] . The inverse correlation between CD4 þ CD73 þ T-cell numbers and plasma CRP levels in HIV-1-positive individuals identifies a possible link between HIV-1 infection and increased rates of cardiovascular disease.
The cause of persistent immune activation and elevated levels of inflammation in chronic HIV-1 infection is unclear. Our study concentrated on why the immunoregulatory mechanisms, specifically the ADO pathway, are unable to control this increased inflammation. Our results support the hypothesis that loss of CD73-expressing CD4 þ T cells and consequently, decreased ADO levels contribute to this lack of control. This loss is associated with increased proportions of activated T cells and systemic inflammation despite virologic suppression during ART. The CD73 þ T-cell subset could, therefore, be a critical factor in the increased rates of HIV-1associated chronic diseases.
